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Abstract
The role of MDM2 in DNA damage signaling
By
Stanley Tam
Advisor: Jill Bargonetti
Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase that negatively regulates the
tumor suppressor p53. MDM2 has tumorigenic capacity because of its ability to inhibit p53mediated apoptosis and cell cycle arrest. In addition, MDM2 is known to function in
tumorigenesis independently of p53. In particular, MDM2 is involved in DNA double-strand
break (DSB) repair, due to its interaction with the Nbs1 subunit of the Mre11-Rad50-Nbs1
(MRN) complex. The MRN complex localizes to DSBs and recruits the DNA damage mediator
ATM, which can then phosphorylate histone H2AX near the break, forming γH2AX. γH2AX
acts as a signal for the localization of DNA repair factors. It has been shown that MDM2
overexpression causes delays in DSB repair, resulting in an increase of DSBs and γH2AX.
Therefore, knockdown of MDM2 should lower γH2AX formation after DNA damage induction.
In order to study the role of MDM2 in DNA damage signaling, we applied DNA
damaging agents on MDM2-overexpressing A875 melanoma and T47D breast cancer and their
respective shMDM2 knockdown lines, and probed for γH2AX. We induced DNA damage by
treating cells with the topoisomerase II inhibitor etoposide or the radiomimetic neocarzinostatin
and then isolated chromatin-associated proteins. After Western blot analysis we observed that
there was a statistically significant increase in γH2AX in the A875 vector control line treated
with etoposide but not the shMDM2 knockdown line. Also, MDM2 knockdown did not lower
γH2AX formation in T47D cells treated with etoposide. These results suggested that the
knockdown of MDM2 may not reverse the effect of MDM2 overexpression on increased γH2AX
levels in response to DNA damage. Instead, MDM2 may be affecting the recruitment of other

iii

DNA repair factors, therefore contributing to genome stability. In the future, it will be interesting
to study if MDM2 influences DNA repair pathway choice by blocking one pathway while
activating another.
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Chapter 1: Introduction
1.1 MDM2
1.1.1 The discovery and functions of MDM2
The mouse double minute 2 (MDM2) gene was discovered in the 3T3-DM cell, a
spontaneously transformed derivative of the mouse 3T3 cell line, which exhibited double minute
extrachromosomal DNA fragments (Cahilly-Snyder et al., 1987). MDM2 was shown to have
tumorigenic potential by providing a growth advantage when overexpressed in 3T3 cells
((Fakharzadeh, Trusko, & George, 1991). The MDM2 protein was shown to bind and inhibit the
transactivation functions of the tumor suppressor p53 (Momand et al., 1992). Later, MDM2 was
shown to be an E3 ubiquitin ligase that could degrade p53 via the ubiquitin-proteasome system,
further cementing the role of MDM2 as an oncogene (Haupt et al., 1997). Additionally,
overexpression of MDM2 in mice with or lacking wild-type p53 leads to spontaneous tumor
formation, suggesting that MDM2 has pro-tumorigenic functions independent of p53 (Jones et
al., 1998).

1.1.2 Regulation of MDM2 expression.
The expression of MDM2 is in part regulated by p53 in a negative feedback loop in
which p53 activates transcription of MDM2 (Juven et al., 1993). MDM2 is transcribed from two
distinct promoters, the P1 promoter, which is responsible for basal transcription and the P2
promoter, which is inducible by p53 (Barak et al., 1994). These two promoters produce two
distinct mRNA transcripts of different lengths (Figure 1) (Barak et al., 1994). Later, it was
shown that a single nucleotide polymorphism (SNP) switch from thymine to guanine at position
309 (SNP309) results in increased expression of MDM2 due to binding of the transcription factor
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Sp1 near the P2 promoter (Bond et al., 2004). Individuals with homozygous G/G at SNP309
have an increased likelihood to develop certain cancers due to MDM2 overexpression (Bond et
al., 2004).
Figure 1 – Differential MDM2 transcription regulation.

Taken from (Manfredi, 2010). MDM2 is expressed from two distinct promoters. The P1
promoter is responsible for basal transcription of MDM2. The P2 promoter is inducible by
transcription factors such as p53. The mRNA transcripts derived from the P1 and P2 promoters
have 5’ untranslated regions of different length.

1.1.3 MDM2 overexpression in cancer
MDM2 was shown to be highly expressed due to gene amplification in a variety of
sarcomas, leading to inhibition of p53-mediated growth regulation (Oliner et al., 1992).
Furthermore, experimental overexpression of MDM2 in mouse mammary tissue leads to
formation of mammary tumors, suggesting that high levels of MDM2 expression has
transformative properties in vivo (Lundgren et al., 1997). MDM2 is also overexpressed in a
broad variety of human cancers such as breast and melanoma, and higher expression typically
correlates with poorer patient survival (reviewed by Rayburn et al., 2005). In particular, MDM2
2

is overexpressed in estrogen receptor alpha positive (ERα+) breast cancers (Hori et al., 2002).
ERα+ breast cancer cell lines such as T47D have high MDM2 levels due to transcription from the
P2 promoter independent of p53 regulation (Phelps et al., 2003).

1.2 DNA damage
1.2.1 DNA damage and repair
DNA damage is a constant threat to both normal and cancerous cells and poses a risk to
their genomic stability. Stress, toxins and radiation either indirectly or directly produce reactive
oxygen species that can damage DNA and drive genome instability (reviewed by Levine et al.,
2017). In particular, DNA double-strand breaks (DSBs) are especially dangerous due to the risk
of major chromosomal damage or loss, and can be generated by radiation and certain
chemotherapeutics (reviewed by Jekimovs et al., 2014). In order to deal with DNA DSBs (and
DNA damage in general), organisms have evolved responses to detect and manage DNA lesions.
One such measure is the Mre11-Rad50-Xrs2 (MRX) complex, which was discovered in
yeast to be important for the repair of DSBs during meiotic recombination (Usui et al., 1998).
The MRX complex is homologous to the Mre11-Rad50-Nbs1 (MRN) complex in mammals. The
MRN complex is required for activation of the DSB mediator ataxia telangiectasia mutated
(ATM) in response to DNA damage (Uziel et al., 2003). ATM is responsible for phosphorylating
a variety of proteins to initiate the DNA damage response (reviewed by Shiloh & Ziv, 2013)
including CHK2, which prevents the cell from entering mitosis before the damage is repaired
((Matsuoka, Huang, & Elledge, 1998). Central to the DNA damage response is the
phosphorylation by ATM of histone H2AX on serine 139 to form γH2AX (Burma et al., 2001).
γH2AX acts as signal for the presence of DNA DSBs which need to be repaired (Rogakou et al.,
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1998). It has been previously shown that MDM2 affects γH2AX formation in cells lacking p53
(Bouska et al., 2008). As detected by Western blot, γH2AX levels are higher in MDM2
overexpressing mouse embryonic fibroblasts (MEFs) exposed to gamma radiation compared to
control MEFs, which shows that MDM2 plays a role in γH2AX signaling (Bouska et al., 2008).
Thus, analyzing γH2AX formation in response to DNA damage could elucidate the role of
MDM2 in the DNA damage response.

Figure 2 – Various exogenous and endogenous causes lead to formation of γH2AX.

Taken from (Georgoulis et al., 2017). Different factors and processes create DNA double-strand
breaks that trigger phosphorylation of histone H2AX into γH2AX.
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Chapter 2: Materials and Methods
2.1 Cell culture – A875 empty vector and constitutive shMDM2 cells were generated by
Melissa Rosso and were obtained from shared laboratory stocks for use in this thesis (Rosso et
al., 2015). T47D empty vector and constitutive shMDM2 cells were generated by Chong Gao
from the Bargonetti lab and were a generous gift (unpublished). A875 cells and T47D cells were
grown in DMEM (Cellgro) supplemented with 5% fetal bovine serum (Gemini), 50 U/ml
penicillin and 50 ug/ml streptomycin (Mediatech) in a 5% CO2, 37ºC humidified incubator.
2.2 Drug treatments – A875 and T47D cells were treated with either 10 μM etoposide (Sigma)
for 3 hours or 100 ng/ml neocarzinostatin (Sigma) for 2 hours in fresh supplemented DMEM.
A875 and T47D cells were harvested by scraping after treatment, washed in cold PBS and spun
at 1100 rpm for 5 min at 4ºC to pellet the cells. Cell pellets were stored at -80ºC until histone
extractions or chromatin fractionations were performed.
2.3 Histone extractions – Cell pellets were lysed in 1 mL of Triton extraction buffer (0.5%
Triton X-100 (v/v), 2 mM phenylmethylsulfonyl fluoride, 0.02% sodium azide (w/v) in PBS) for
10 minutes in ice. After centrifugation at 1200 rpm for 10 minutes, the supernatant was discarded
and the pellets were rotated overnight in 0.2 N hydrochloric acid with 1:100 phosphatase
inhibitor cocktail (Sigma) at 4°C. The next day, the samples were centrifuged at 1200 rpm for 10
minutes, and the supernatant (histone extract) was stored at −20°C.
2.4 Chromatin fractionations – Cell pellets were lysed in Buffer A (10 mM HEPES, 10 mM
KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 0.5 mM PMSF, 2 ug/ml
Leupeptin, 8.5 ug/ml Aprotinin, 1:100 phosphatase inhibitor cocktail and 0.1% Triton X-100) on
ice for 5 minutes. The solution was spun down at 3600 rpm for 5 minutes, and supernatant was
5

collected as the S1 cytosolic fraction. The pellet was washed twice in Buffer A, and the resulting
pellet was resuspended in Buffer B (3 mM EDTA, 0.2 mM EGTA, 2 ug/ml Leupeptin, 8.5 ug/ml
Aprotinin and 1:100 phosphatase inhibitor cocktail), and vortexed every 5 minutes for 30
minutes. The solution was spun down at 3600 rpm for 5 minutes, and supernatant was collected
as the S2 nuclear soluble fraction. The pellet was washed twice in Buffer B and the resulting
pellet was resuspended in Buffer B, sonicated 3 times for 30 seconds at 97 amplitude and
collected as the P3 chromatin fraction. All samples were stored at −80°C.
2.5 Western blot analysis – To twenty microgram histone aliquots, 4X NuPAGE LDS buffer
(Invitrogen) and DTT (Sigma) were added such that the working concentrations were 1X
NuPAGE and 50 mM DTT. The samples were boiled at 70°C for 10 mins and iodoacetamide
was added to reach 100 mM. The samples separated by either 10% or 4-12% (Invitrogen) SDSPAGE, wet transferred to PVDF membranes, blocked in 5% nonfat milk in TBS with 0.1%
Tween-20. The membranes were probed with primary antibodies overnight at 4°C. The next day,
the membranes were washed in TBS with Tween-20, and probed with secondary antibodies at
room temperature for 1 hour. The membranes were dried in a 37°C incubator and scanned using
the TyphoonTM FLA 7000 (GE Healthcare). Images were analyzed using ImageQuant TL v8.1
software (GE Healthcare), ImageJ 1.50i (National Institutes of Health) and the data was graphed
using Prism v7.0c (Graphpad Software).
2.6 Antibodies – Primary antibodies used for Western Blots were α-γH2AX (EMD Millipore 05636), α-H2B (EMD Millipore 07-371), α-Lamin (Sigma L1293) and a mixture of α-MDM2
monoclonal antibodies 4B2, 2A9 and 4B11. Secondary antibodies used were α-mouse IgG-Cy3
(GE Healthcare) and α-rabbit IgG-Cy5 (GE Healthcare). Primary antibodies were of different
animal origins and thus were probed together on the same membrane.
6

Chapter 3: The role of MDM2 in DNA damage signaling and repair.
3.1 Introduction
Recent studies are starting to uncover the role of MDM2 in increasing genome instability,
which may be beneficial for the progression of certain cancers (reviewed by Saadatzadeh et al.,
2017). MDM2 has been shown to act as E3 ubiquitin ligase to degrade proteins related to the
DNA damage response and cell cycle control including the p53 family (p53, p63, p73), pRB and
CHK2 (reviewed by Riley & Lozano, 2011). In addition to degrading proteins that control
genome integrity, MDM2 was shown to bind the Nbs1 subunit of the MRN complex (Alt et al.,
2005). Nbs1 is required for efficient recruitment of ATM to DSBs, which is important for the
subsequent localization of DNA repair factors by ATM (Falck et al., 2005).
MDM2 overexpression was shown to delay the repair of DSBs induced by gamma
irradiation in vitro (Bouska et al., 2008). The effects of MDM2 overexpression were abrogated
by mutating the MDM2 residues that interact with Nbs1 (Bouska et al., 2008). After gamma
irradiation, MDM2 overexpressing MEFs had higher γH2AX levels compared to controls
(Bouska et al., 2008) which suggests that MDM2 may be affecting DNA damage signaling
through Nbs1. However, it has not been shown if the knockdown of MDM2 reduces γH2AX
formation after DNA damage induction. We tested the role of MDM2 in γH2AX formation by
causing DNA damage in MDM2 overexpressing cells using the topoisomerase II inhibitor
etoposide or the radiomimetic neocarzinostatin (NCS). A875 melanoma cells and T47D ERα+
breast cancer cells both have homozygous G/G SNP309 overexpression of MDM2 (Table 1).
The extent of γH2AX formation in these cells was compared to A875 and T47D with MDM2
knockdown via constitutively expressed shRNA.
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Table 1 – Cell lines used in this study.
Cell line

p53 status

A875
T47D

Wild-type
Mutant

MDM2 SNP309
status
G/G homozygous
G/G homozygous

Cell type
Melanoma
Breast cancer

3.2 Results
3.2.1 MDM2 knockdown lowers γH2AX formation in response to DNA damage in A875
cells but not T47D cells.
A875 and T47D cells and their respective MDM2 knockdown lines were used to compare
the extent of γH2AX formation after DNA damage induction. In A875 vector control cells,
etoposide treatment significantly increased γH2AX levels, however in the MDM2 knockdown
line there was no significant increase (Figure 3A and B). This suggests that high levels of
MDM2 were contributing to greater DNA damage and thus γH2AX formation in A875 cells.
However, in T47D cells the initial one time data suggested that MDM2 overexpression before
knockdown did not result in increased DNA damage as assessed by γH2AX levels. Both T47D
vector control and MDM2 knockdown cells had similar levels of γH2AX with either etoposide or
NCS treatment (Figure 3C and D). This suggested that MDM2 did not play a role in γH2AX
signaling in T47D cells. Further testing of γH2AX levels in chromatin fractions showed that
MDM2 knockdown did not lower γH2AX in T47D cells treated with etoposide, although there
was a statistically significant increase in γH2AX in the untreated controls (Figure 3E and F). The
level of MDM2 protein in untreated T47D cells was decreased by about 65% between the vector
control and shMDM2 lines (Figure 3G).
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Figure 3 – MDM2 knockdown lowers γH2AX formation in response to DNA damage in
A875 cells but not T47D cells.

9

Figure 3 – A875 and T47D MLP vector and MDM2 shRNA constitutive knockdown cells were
treated with 10 μM etoposide for 3 hours or 100 ng/ml neocarzinostatin (NCS) for 2 hours. Cells
were harvested and subjected to either histone extractions or chromatin fractionations. A, C)
Histone extracts were run using SDS-PAGE and probed for γH2AX and H2B as a loading
control. A representative image is shown. B) Relative intensity of γH2AX was normalized
against H2B and averaged over 3 independent experiments. The non-significant p value was
0.118. D) Relative intensity of γH2AX was normalized against H2B in one experiment. E) T47D
chromatin extracts were run using SDS-PAGE and probed for γH2AX, MDM2 (mix of 4B2, 2A9
and 4B11) and Lamin as a loading control. A representative image is shown. F) Relative
intensity of γH2AX was normalized against Lamin and averaged over 3 independent
experiments. G) Relative intensity of MDM2 in T47D cells was normalized against Lamin and
averaged over 2 independent experiments. * represents a p value < 0.05. *** represents a p value
< 0.0005. NS represents a non-significant p value > 0.05. Student’s t test was used for statistical
analysis.

3.3 Discussion
One of the ways MDM2 induces genome instability is by binding to Nbs1 and delaying
DSB repair, leading to accumulation of DNA damage (reviewed by Eischen, 2016). Although
γH2AX formation appears significantly different in A875 cells overexpressing MDM2 compared
to the shRNA knockdown, it is not yet determined if and how it is biologically significant. While
there was a statistically significant increase in γH2AX levels in A875 vector controls cells
treated with etoposide, the same was not observed in A875 MDM2 knockdown cells (Figure 3B).
However, the p value (0.118) for the A875 shMDM2 cells treated with etoposide approached
statistical significance, suggesting that γH2AX formation is not affected by a decrease of MDM2
(Figure 3B). Therefore, it is possible that DNA damage signaling and repair mechanisms may
still function normally even after MDM2 knockdown. Moreover, in T47D cells treated with
etoposide, there were statistically significant increases of γH2AX in both vector control and
shMDM2 lines (Figure 3F). This suggests that MDM2 knockdown does not lower γH2AX
formation after DNA damage induction in cells overexpressing MDM2. Also, there was a
statistically significant increase in γH2AX in the untreated T47D cells with MDM2 knockdown
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compared to the vector control (Figure 3F), but it is not yet clear if this difference affects DNA
repair. Although the MDM2 knockdown in T47D untreated cells was efficient (Figure 3G), it is
possible that the decrease in MDM2 is not significant enough to lower γH2AX formation.
γH2AX levels may not be meaningfully altered because other DNA repair mediators also
phosphorylate H2AX, such as DNA-PK (An et al., 2010). The lack of a decrease of γH2AX
levels in T47D cells with MDM2 knockdown suggests that MDM2 may weaken genome
stability through targets other than Nbs1. It is possible that γH2AX formation is not particularly
important for proper DNA repair in MDM2 overexpressing cancers and that other pathways
decrease genome stability. As an alternative, the increase of γH2AX formation due to MDM2
overexpression (Bouska et al., 2008) could instead be acting as a more robust signal to recruit a
different variety of DNA repair factors. In order to clarify the role of MDM2 overexpression in
DNA repair, it would be necessary to identify which DNA repair factors associate at DSBs and
test if these factors are responsible for modifying DNA repair pathway choice.

Chapter 4: Future directions
MDM2 overexpression appears to increase γH2AX in response to DNA damage in A875
cells but not T47D cells. However, it is still not known if MDM2 alters DNA repair pathway
choice. Cells use two major repair pathways to resolve DSBs, nonhomologous end-joining
(NHEJ) and homologous recombination (HR), with the former being more error-prone than the
latter (reviewed by Jekimovs et al., 2014). It would be interesting to see if MDM2
overexpression creates bias towards one of these DNA repair mechanisms. Since the pro-HR
factor BRCA1 and the pro-NHEJ factor 53BP1 antagonize each other (Bunting et al., 2010), it is
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possible to determine if MDM2 affects the choice between HR and NHEJ. In order to test this,
knocking down either BRCA1 or 53BP1 with shRNA and quantifying the extent of DNA
damage should show if MDM2 overexpression supports one pathway over another. Another
DSB repair pathway, microhomology-mediated end joining (MMEJ), is an alternative repair
pathway that cells can use but is highly mutagenic (Sinha et al., 2017). It was shown that ATM
represses MMEJ, suggesting that ATM may protect genome integrity by inhibiting this type of
DNA repair (Rahal et al., 2010). Interestingly, MMEJ requires the nuclease function of Mre11 of
the MRN complex, which MDM2 may alter due to its interaction with Nbs1 (Truong et al.,
2013). If MDM2 overexpression increases the use of MMEJ, then inhibiting the nuclease activity
of Mre11 by mutation and testing if MMEJ is still active should show if MDM2 is involved in
this pathway. In conclusion, the role of MDM2 in genome instability still has not been explored
thoroughly but could be improved by studying predispositions in DNA repair pathway choice.
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